KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) Operating Margin (2017 - 2025)

Sarepta Therapeutics has reported Operating Margin over the past 12 years, most recently at 92.92% for Q4 2025.

  • For Q4 2025, Operating Margin fell 11748.0% year-over-year to 92.92%; the TTM value through Dec 2025 reached 31.83%, down 4330.0%, while the annual FY2025 figure was 31.83%, 4330.0% down from the prior year.
  • Operating Margin for Q4 2025 was 92.92% at Sarepta Therapeutics, down from 25.89% in the prior quarter.
  • Over five years, Operating Margin peaked at 24.56% in Q4 2024 and troughed at 948.91% in Q2 2022.
  • A 5-year average of 159.94% and a median of 33.11% in 2025 define the central range for Operating Margin.
  • Biggest five-year swings in Operating Margin: skyrocketed 78902bps in 2021 and later tumbled -84678bps in 2022.
  • Year by year, Operating Margin stood at 52.52% in 2021, then soared by 74bps to 13.75% in 2022, then skyrocketed by 117bps to 2.28% in 2023, then surged by 975bps to 24.56% in 2024, then plummeted by -478bps to 92.92% in 2025.
  • Business Quant data shows Operating Margin for SRPT at 92.92% in Q4 2025, 25.89% in Q3 2025, and 18.91% in Q2 2025.